Articles from Oligomerix, Inc.

Oligomerix, Inc., a privately held clinical stage company pioneering the development of oral, small molecule therapeutics targeting Alzheimer’s (AD) and rare neurodegenerative diseases, announced an NIH Fast Track award of $0.5 million from the National Institute on Aging of the National Institutes of Health. This grant supports clinical development of OLX-07010, its orally administered, investigational drug, targeting pathological tau aggregates that drive the progression of AD.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the election of William Caple as its new Chairman of the Board of Directors.

Oligomerix, Inc., a clinical-stage biotechnology company pioneering the development of a platform of protein self-association inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced today the publication of a preclinical study demonstrating in vivo proof of concept for therapeutic treatment with its oral small molecule OLX-07010 blocking the progression of tau aggregation and ameliorating motor deficits.

Oligomerix, Inc., a clinical-stage biotechnology company pioneering the development of a platform of tau self-association inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced today the publication of preclinical data demonstrating that the oral small molecule OLX-07010 inhibits tau aggregation in a model for inherited tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Earlier this year, Oligomerix announced first-in-human dosing of OLX-07010 in a Phase 1a clinical trial.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases today announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010. This lead compound is a novel oral, small molecule inhibitor of tau self-association being assessed for the treatment of Alzheimer’s disease and other neurodegenerative disorders.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau Oligomers.” The ‘776 patent further strengthens the company’s intellectual property position and coverage for their tau oligomer formation inhibitors and provides product protection for Oligomerix’s lead clinical candidate, OLX-07010, including composition of matter and methods of use until October 2037.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings in November 2022.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $2.49 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor. In August, Oligomerix announced a separate R01 NIH award of $3.35 million to support a Phase 1a clinical trial of OLX-07010 in healthy subjects, expected to begin this year.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $3.35 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor. Oligomerix plans to begin a Phase 1a clinical trial in healthy volunteers in 2022.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced several organizational changes reflecting the transition to a clinical-stage pharmaceutical company.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an extension of its Series B funding round, raising $2.7 million. Funding from the Series B will allow Oligomerix to accelerate its transition into Phase 1 human clinical development planned for early 3Q 2022.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at the Society for Neuroscience’s (SfN) 50th annual meeting Neuroscience 2021.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company will deliver a virtual oral presentation at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference, being held in Boston on November 9-12, 2021.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company presented at the 2021 Alzheimer's Association International Conference (AAIC) in a presentation titled “In vivo validation of therapeutic efficacy of a small molecule lead targeting tau self-association in JNPL3 mice.”

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the Company will be presenting preclinical data on its oral, tau self-association small molecule inhibitor lead program, OLX-07010, at the 2021 Alzheimer's Association International Conference (AAIC), which will be held from July 26-30 in Denver and online. Oligomerix plans to complete preclinical testing of OLX-07010 by year end and begin Phase 1 clinical trials by 2Q22.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the appointment of William Erhardt, M.D., Chief Medical Officer of Oligomerix, to its Board of Directors.

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that President and CEO James Moe, Ph.D., MBA will be participating in upcoming life sciences conferences in June.